Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$67.52-2.24%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TARS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks TARS against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to increase sales of XDEMVY, the lead product for Demodex blepharitis, through commercial execution and direct-to-consumer marketing.
Stated as a priority in 2 of last 2 quarters. XDEMVY net product sales grew from $145.4 million in 2026-Q1 to $173.9 million in 2026-Q2, a year-over-year increase exceeding 69%. Management increased full-year 2026 sales guidance to $685-705 million. The trajectory is delivering consistent growth and expanding market adoption.
“XDEMVY generated second quarter 2026 net product sales of $173.9 million, a year-over-year increase of more than 69%.”
“XDEMVY net product sales of more than $145 million, an increase of more than 85% year-over-year.”
Progress clinical development programs and expand pipeline through strategic acquisitions to build a leading eye care company.
Stated as a priority in 3 disclosures including 2026-Q2 and two 2026-08/09 announcements. Management completed acquisitions of iRenix Medical and Alkeus Pharmaceuticals, adding late-stage clinical assets IRX-101 and ALK-001. Pipeline advancement includes ongoing Phase 3 NORTHSTAR trial with topline data expected in 2029. The trajectory shows active expansion and clinical progress.
“Pending acquisition of Alkeus Pharmaceuticals to expand Tarsus’ retina pipeline with a Phase 3 clinical program for Stargardt disease.”
Increase patient and prescriber awareness of Demodex blepharitis and XDEMVY through direct-to-consumer campaigns and promotional efforts.
Stated as a priority in 2 of last 2 quarters. Direct-to-consumer marketing increased website engagement by over 30% in 2026-Q2 and 40% quarter-over-quarter in 2026-Q1, with unaided awareness rising from 2% to approximately 30%. These efforts support prescription growth and deeper market penetration, indicating delivering progress.
“Direct-to-consumer initiatives continued to contribute to prescription growth and awareness; website engagement increased by more than 30%.”
Ensure smooth transitions in executive leadership to support company growth and commercial execution.
Stated as a priority in 2 disclosures including 2026-Q2. Management appointed an interim Chief Commercial Officer following the departure of the prior CCO. This priority reflects active management of leadership changes to maintain commercial momentum. The trajectory is ongoing with recent appointments.
“Appointed Neera Clase, Interim Chief Commercial Officer as the Company enters its next phase of growth.”
Raise the annual sales guidance for XDEMVY to reflect strong commercial performance and market demand.
Stated as a priority in 2 of last 2 quarters. Management raised full-year 2026 XDEMVY net product sales guidance from $670-700 million in 2026-Q1 to $685-705 million in 2026-Q2, reflecting confidence in continued sales growth. The trajectory matches the improving commercial performance.
“Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million.”
Over the trailing year it converted 1.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“Direct-to-Consumer campaign drove tremendous engagement with high-value website actions up approximately 40% quarter-over-quarter.”
“Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales.”